Evidence Snapshot

Norepinephrine transporter

CHEMBL304 SINGLE PROTEIN Rattus norvegicus

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:27:40Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 1:27 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL304

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Norepinephrine transporter as ChEMBL target CHEMBL304, mapped to UniProt Q9WTR4. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Norepinephrine transporter

SINGLE PROTEIN · Rattus norvegicus

As of 2026-09-13

ChEMBL target ID

CHEMBL304

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q9WTR4

Transporter

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Norepinephrine transporter matters

As of 2026-09-13

Norepinephrine transporter is reviewed as Transporter (UniProt Q9WTR4); the current evidence base includes 44 approved drugs, 1663 compounds, and 184 assays, with lead potency reaching pChEMBL 9.9.

Protein context

Transporter

Transporter Sequence length is 597 aa.

Review this target as Norepinephrine transporter, mapped to UniProt Q9WTR4. ChEMBL maps the protein component as Transporter. Sequence length is 597 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q9WTR4 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 44 approved drugs, 1663 compounds, and 184 assays for this target. The dominant activity type is KI. CHEMBL544500 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL544500 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine

44 approved pChEMBL 9.9

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Norepinephrine transporter matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9WTR4, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1663

Total Compounds

184

Total Assays

Approved Drugs

IC50: 818.0, KI: 1200.0, EC50: 25.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL544500	9.9	IC50	—
No preferred name CHEMBL540617	9.8	Ki	—
No preferred name CHEMBL1743782	9.8	Ki	—
No preferred name CHEMBL1743810	9.7	Ki	—
No preferred name CHEMBL2093944	9.7	Ki	—